{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:53:00Z","timestamp":1790009580234,"version":"4.0.1"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Complement C5 inhibitors are effective disease-modifying therapies for acetylcholine receptor antibody-positive generalized myasthenia gravis (MG), but cardiovascular safety has not been evaluated as a dedicated outcome domain. With increasing and prolonged use, systematic assessment of cardiovascular and thromboembolic risk - including potential differences between individual C5 inhibitors - is needed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a retrospective cohort study using the TriNetX federated electronic health record network, including adults with generalized MG. Propensity score-matched cohorts compared patients treated with C5 inhibitors with untreated controls (N\u00a0=\u00a01,094 vs. 1,094), and ravulizumab with eculizumab (N\u00a0=\u00a0330 vs. 330). Outcomes included major adverse cardiovascular events (MACE), thrombotic disorders, acute kidney injury (AKI), arrhythmias, and all-cause mortality over 365 days. Associations were evaluated using risk ratios (RR) and Cox proportional hazards models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After matching, C5 inhibition was associated with increased risk of AKI (6.1% vs 3.2%, p&amp;lt;0.01; RR 1.70) and thrombotic disorders (5.1% vs 2.6%, p=0.002; RR 1.74) compared to no C5-inhibition treatment. All-cause mortality was significantly lower among C5-treated patients after one year (RR 0.54; p=0.045). MACE occurred more frequently with C5 inhibition (8.3% vs 5.5%; p=0.009), with a trend toward higher hazard over time. In agent-specific analyses (ravulizumab vs. eculizumab), ravulizumab was associated with a significantly lower hazard of MACE compared with eculizumab (6.6% vs 11.1%, p=0.041; HR 0.58, while hazards for mortality, thrombotic events, and other cardiovascular outcomes were similar.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>C5 inhibition in generalized MG is associated with improved survival but increased cardiovascular and thromboembolic risk. Although limited by its retrospective design, this analysis highlights a clinically relevant safety signal and suggests heterogeneity within the C5 inhibitor class. As use of complement inhibition expands, careful longitudinal cardiovascular monitoring will become increasingly important for clinicians managing patients with MG.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1812643","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T05:46:00Z","timestamp":1778737560000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Complement C5 inhibition in generalized myasthenia gravis is associated with improved survival and increased cardiovascular risk"],"prefix":"10.3389","volume":"17","author":[{"given":"Carl","family":"Vahldieck","sequence":"first","affiliation":[{"name":"Department of Anesthesiology and Intensive Care Medicine, University Medical Centre Schleswig-Holstein","place":["Luebeck, Germany"]},{"name":"Institute of Physiology, University of Luebeck","place":["Luebeck, Germany"]},{"name":"DZHK (German Research Centre for Cardiovascular Research), Partner Site North","place":["Luebeck, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikt","family":"Fels","sequence":"additional","affiliation":[{"name":"Institute of Physiology, University of Luebeck","place":["Luebeck, Germany"]},{"name":"DZHK (German Research Centre for Cardiovascular Research), Partner Site North","place":["Luebeck, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(09)70063-8","article-title":"Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity","volume":"8","author":"Meriggioli","year":"2009","journal-title":"Lancet Neurol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10112235","article-title":"Myasthenia gravis: epidemiology, pathophysiology and clinical manifestations","volume":"10","author":"Dresser","year":"2021","journal-title":"J Clin Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-025-04271-9","article-title":"Circulating inflammatory cytokines and the risk of myasthenia gravis: a bidirectional Mendelian randomization study","volume":"25","author":"Su","year":"2025","journal-title":"BMC Neurol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/s41392-025-02220-z","article-title":"The immune system in cardiovascular diseases: from basic mechanisms to therapeutic implications","volume":"10","author":"Wang","year":"2025","journal-title":"Sig Transduct Target Ther"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1186\/s12872-026-05752-6","article-title":"Complement C5 inhibition with eculizumab or ravulizumab is associated with increased cardiovascular and thromboembolic risk after ST-elevation myocardial infarction: a propensity-matched global retrospective cohort study","volume":"26","author":"Vahldieck","year":"2026","journal-title":"BMC Cardiovasc Disord"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtauto.2024.100259","article-title":"Autoimmune diseases and cardiovascular risk: Mendelian randomization analysis for the impact of 19 autoimmune diseases on 14 cardiovascular conditions","volume":"9","author":"Bao","year":"2024","journal-title":"J Transl Autoimmun"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2023.103447","article-title":"Risk of venous thromboembolism in autoimmune diseases: a comprehensive review","volume":"22","author":"Menichelli","year":"2023","journal-title":"Autoimmun Rev"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"EVIDoa2100066","DOI":"10.1056\/evidoa2100066","article-title":"Terminal complement inhibitor ravulizumab in generalized myasthenia gravis","volume":"1","author":"Vu","year":"2022","journal-title":"NEJM Evid"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2021.577767","article-title":"Eculizumab treatment for myasthenia gravis subgroups: 2021 update","volume":"362","author":"Jiao","year":"2022","journal-title":"J Neuroimmunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-023-11699-x","article-title":"Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: final results from the phase 3 CHAMPION MG open-label extension","volume":"32","author":"Vu","year":"2025","journal-title":"Eur J Neurol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.52051","article-title":"Real-world experience with eculizumab and switching to ravulizumab for generalized myasthenia gravis","volume":"11","author":"Tokuyasu","year":"2024","journal-title":"Ann Clin Transl Neurol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.70278","article-title":"Effectiveness and safety of switching to ravulizumab from eculizumab in kidney transplant recipients with atypical hemolytic uremic syndrome: a global aHUS registry analysis","volume":"39","author":"Gaeckler","year":"2025","journal-title":"Clin Transplant"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2025.123628","article-title":"First analysis of the Myasthenia Gravis SPOTLIGHT Registry: outcomes with eculizumab and ravulizumab","volume":"476","author":"Howard","year":"2025","journal-title":"J Neurol Sci"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14228205","article-title":"Complement inhibitors in generalized myasthenia gravis: comparison of administration schedules, efficacy, and safety","volume":"14","author":"Di Martino","year":"2025","journal-title":"J Clin Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1186\/s12882-024-03638-3","article-title":"Clinical efficacy and safety of switching from eculizumab to ravulizumab in adult patients with aHUS\u2013 real-world data","volume":"25","author":"Sch\u00f6nfelder","year":"2024","journal-title":"BMC Nephrol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1667249","article-title":"Safety profile of complement C5 inhibitors and FcRn inhibitors in the treatment of myasthenia gravis: analysis of the FAERS database and disease-gene interaction network","volume":"16","author":"Wang","year":"2025","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2024-334404","article-title":"C5 complement inhibition versus FcRn modulation in generalised myasthenia gravis","volume":"96","author":"Huntemann","year":"2025","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000200331","article-title":"Ravulizumab and efgartigimod in myasthenia gravis: a real-world study","volume":"12","author":"Stascheit","year":"2025","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021012860","article-title":"Advancing therapeutic complement inhibition in hematologic diseases: PNH and beyond","volume":"139","author":"Gavriilaki","year":"2022","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-023-03630-x","article-title":"Real-world safety profile of eculizumab in patients with paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, or generalized myasthenia gravis: an integrated analysis of post-marketing surveillance in Japan","volume":"118","author":"Nishimura","year":"2023","journal-title":"Int J Hematol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.10.060","article-title":"Comparison of propensity score methods and covariate adjustment: evaluation in 4 cardiovascular studies","volume":"69","author":"Elze","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/jlme.12060","article-title":"Currents in contemporary ethics. Research privacy under HIPAA and the common rule","volume":"33","author":"Rothstein","year":"2005","journal-title":"J Law Med Ethics"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.105485","article-title":"Biological, as opposed to classic antipsoriatic drug or apremilast, treatment mitigates the risk of death and cardiovascular disease in psoriasis","volume":"111","author":"Kridin","year":"2025","journal-title":"EBioMedicine"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.2147\/ndt.s374694","article-title":"Ravulizumab in myasthenia gravis: a review of the current evidence","volume":"19","author":"Vu","year":"2023","journal-title":"Neuropsychiatr Dis Treat"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1212\/wnl.0000000000204425","article-title":"Effectiveness and safety of transitioning to ravulizumab from eculizumab in patients with generalized myasthenia gravis: evidence from a global registry (P10-11.002)","volume":"102","author":"Sabatella","year":"2024","journal-title":"Neurology"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2024000544","article-title":"Catastrophic antiphospholipid syndrome: a CAPS-tivating hematologic disease","volume":"2024","author":"Salter","year":"2024","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2025000702","article-title":"Update in the diagnosis of complement-mediated thrombotic microangiopathy\/atypical hemolytic uremic syndrome","volume":"2025","author":"Cole","year":"2025","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14072527","article-title":"Atypical hemolytic uremic syndrome: a review of complement dysregulation, genetic susceptibility and multiorgan involvement","volume":"14","author":"Bogdan","year":"2025","journal-title":"J Clin Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1426526","article-title":"Dysregulated complement activation during acute myocardial infarction leads to endothelial glycocalyx degradation and endothelial dysfunction via the C5a:C5a-receptor1 axis","volume":"15","author":"Vahldieck","year":"2024","journal-title":"Front Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1538563","article-title":"Incidence of infection associated with eculizumab: a meta-analysis of 9 randomized controlled trials","volume":"16","author":"Jiang","year":"2025","journal-title":"Front Pharmacol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0332073","article-title":"Eculizumab and ravulizumab clinical trial and real-world pharmacovigilance of meningococcal infections across indications","volume":"20","author":"Carrillo Infante","year":"2025","journal-title":"PloS One"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1172\/jci188345","article-title":"Role of local complement activation in kidney fibrosis and repair","volume":"135","author":"Portilla","year":"2025","journal-title":"J Clin Invest"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2025.06.005","article-title":"Role of the complement system in acute kidney injury: a narrative review","volume":"100","author":"Wei","year":"2025","journal-title":"Mayo Clin Proc"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1460317","article-title":"Case report: timing of eculizumab treatment in catastrophic antiphospholipid syndrome","volume":"15","author":"Carrara","year":"2024","journal-title":"Front Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010817","article-title":"Complement and platelets: prothrombotic cell activation requires membrane attack complex-induced release of danger signals","volume":"7","author":"Mannes","year":"2023","journal-title":"Blood Adv"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024027574","article-title":"Breakthrough hemolysis in paroxysmal nocturnal hemoglobinuria throughout clinical trials: from definition to clinical practice","volume":"146","author":"Fattizzo","year":"2025","journal-title":"Blood"},{"key":"B39","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s00277-025-06193-5","article-title":"Ravulizumab demonstrates long-term efficacy, safety and favorable patient survival in patients with paroxysmal nocturnal hemoglobinuria","volume":"104","author":"Kulasekararaj","year":"2025","journal-title":"Ann Hematol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11112924","article-title":"Prolonged door-to-balloon time leads to endothelial glycocalyx damage and endothelial dysfunction in patients with ST-elevation myocardial infarction","volume":"11","author":"Vahldieck","year":"2023","journal-title":"Biomedicines"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26209931","article-title":"Functional roles of the complement immune system in cardiac inflammation and hypertrophy","volume":"26","author":"Hok","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2022.12.009","article-title":"Endothelial glycocalyx and cardiomyocyte damage is prevented by recombinant syndecan-1 in acute myocardial infarction","volume":"193","author":"Vahldieck","year":"2023","journal-title":"Am J Pathol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1007\/s11481-021-10030-7","article-title":"Increased expression of CD95 in CD4+ effector memory T cells promotes Th17 response in patients with myasthenia gravis","volume":"17","author":"Huang","year":"2022","journal-title":"J Neuroimmune Pharmacol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2026.119073","article-title":"Amlodipine improves aortic dysfunction in atherosclerotic mice","volume":"196","author":"Rasch","year":"2026","journal-title":"Biomedicine Pharmacotherapy"},{"key":"B45","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41540-025-00488-z","article-title":"Dysregulated autoantibodies targeting AGTR1 are associated with the accumulation of COVID-19 symptoms","volume":"11","author":"Fonseca","year":"2025","journal-title":"NPJ Syst Biol Appl"},{"key":"B46","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/ijlh.14281","article-title":"Complement inhibition in paroxysmal nocturnal hemoglobinuria: from biology to therapy","author":"Versino","year":"2024","journal-title":"Int J Lab Hematol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1007\/s00415-025-12922-7","article-title":"Myasthenia gravis in 2025: five new things and four hopes for the future","volume":"272","author":"Binks","year":"2025","journal-title":"J Neurol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13783","article-title":"Long-term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2-year results from two pivotal phase 3 studies","volume":"109","author":"Kulasekararaj","year":"2022","journal-title":"Eur J Haematol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2024.285553","article-title":"Terminal complement inhibition and control of hemolysis in patients with paroxysmal nocturnal hemoglobinuria who switched from high-dose eculizumab to ravulizumab: a phase IV, single-arm clinical trial","volume":"110","author":"Griffin","year":"2025","journal-title":"Haematologica"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1812643\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T05:46:00Z","timestamp":1778737560000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1812643\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,14]]},"references-count":49,"alternative-id":["10.3389\/fimmu.2026.1812643"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1812643","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,14]]},"article-number":"1812643"}}